98%
921
2 minutes
20
Introduction Potentially surgical brain metastases are increasingly common in patients aged 80 and older, yet the risk-benefit profile of surgical resection in this population remains inadequately defined. Surgical intervention in octogenarians carries a high risk due to systemic issues associated with advanced age and prevalent comorbidities, and data on perioperative morbidity and functional outcomes are limited. Methods A retrospective case series including six patients aged 80 years and older who underwent craniotomy for the resection of brain metastases at a single tertiary care center was conducted. Preoperative and postoperative functional status were assessed. Surgical complications, discharge disposition, and survival outcomes were reviewed through detailed chart analysis and follow-up data. Due to the limited sample size (N=6), no formal statistical analysis was performed. Results Preoperative Karnofsky Performance Status (KPS) averaged 68, and postoperative KPS was 80. One (17%) patient experienced a postoperative hemorrhage necessitating reoperation. Discharge dispositions included two (33%) patients discharged home, three (50%) patients discharged to acute rehabilitation, and one (16%) patient discharged to a skilled nursing facility; all patients discharged to outside facilities ultimately returned home. The median survival time was 13 (range: 2-48) months. Conclusion Surgical resection in patients over 80 years undergoing craniotomy for brain metastases is associated with elevated systemic risk related to comorbidities and systemic disease burden. However, specific patients may benefit, particularly those with large lesions with well-controlled systemic disease and limited medical comorbidity. Deaths observed in this cohort were attributable to systemic disease unrelated to the surgical intervention or intracranial disease. Given the very small sample size, these findings are exploratory and require confirmation with larger studies. Surgical intervention for this population should be considered on a case-by-case basis, with a focus on patients who are neurologically symptomatic with good systemic disease control.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414251 | PMC |
http://dx.doi.org/10.7759/cureus.89602 | DOI Listing |
PLoS One
September 2025
Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Background: Attention to existential needs has become part of daily treatment. Studies have described the concepts of existential experiences and existential interventions. However, a consensus or conceptual clarity regarding an existential approach in cancer patients is currently missing.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.
Neurosurg Rev
September 2025
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne, Paris, F-75014, France.
Awake craniotomy is the gold standard to achieve maximal safe resection of brain lesions located within eloquent areas. There are no established guidelines to assess patient's eligibility for awake craniotomy by weight class. This study assesses feasibility, safety, and efficacy of awake surgery by weight classes through an observational, retrospective, single-institution cohort analysis (2010-2024) of 526 awake craniotomies.
View Article and Find Full Text PDFNeurosurg Rev
September 2025
Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece.
Background: The aim of this review is to present the role of intraoperative flow cytometry (IFC) in the intracranial tumor surgery. This scoping review aims to summarize current evidence on the intraoperative use of IFC in patients with intracranial tumors.
Methods: A comprehensive literature search was conducted in the Medline, Cochrane and Scopus databases up to January 21, 2025.
JCI Insight
September 2025
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada.
More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma.
View Article and Find Full Text PDF